We review recently published literature concerning early morbidity and mortality during antiretroviral therapy (ART) among patients in resource-limited settings. We focus on articles providing insights into this burden of disease and strategies to address it.
Introduction
In 2007 an estimated 33 million people worldwide were living with HIV and 2.0 million died [1] . Over 90% of infected people were in resource-limited settings, with sub-Saharan Africa accounting for 22.0 million of these and south and south-east Asia, Latin America and east and central Europe accounting for 4.2 million, 1.7 million and 1.5 million people, respectively [1] . Following the commitment of United Nations member states to provide universal access to prevention, treatment, care and support by 2010, substantial progress has been made in scaling up antiretroviral treatment (ART) [2] . By the end of 2008, between 3.8 and 4.3 million people in resource-limited settings were estimated to have started ART, with sub-Saharan Africa accounting for approximately 3.0 million of these [3] .
One of the key clinical and programmatic challenges to scale-up of ART in resource-limited settings is the very high rates of mortality and morbidity within the first year of treatment [4,5 ,6 ] . In this article, we review recent literature concerning this issue in adult patients. A large proportion of the literature arises from studies conducted in sub-Saharan Africa which has borne the brunt of the epidemic. However, we acknowledge that there is likely to be considerable geographical variation in the magnitude, causes and potential solutions to this problem.
Mortality
Considerable literature has now accumulated concerning the rates, risk factors and temporal distribution of mortality in ART programmes, but data on causes of death are comparatively scarce.
Mortality risk
A study published in 2006 by the Antiretroviral Therapy in Low Income Countries (ART-LINC) Collaboration was one of the first studies to highlight the disproportionately high mortality of patients treated in resource-limited settings compared with those treated in high-income settings [4] . Despite similar immunological and virological responses to ART, patients treated in low-income settings had a several-fold greater risk of death in the initial months of treatment, even after adjustment for baseline characteristics [4] .
A subsequent review of data from sub-Saharan Africa included 18 ART cohort studies published between 2002 and 2008 [5 ] . These cohorts had median baseline CD4 cell counts ranging between 43 and 147 cells/ml and represented almost 40 000 patients. Substantial mortality accrued in each of these cohorts; Kaplan-Meier estimates ranged between 8 and 26% during the first year of ART and only two cohorts reported estimates of less than 10%. These high rates may even be underestimates, as a recent meta-analysis confirms earlier reports that in some cohorts in sub-Saharan Africa a substantial proportion of patients initially classified as 'lost to followup' have actually died [7] .
Tuboi et al.
[6 ] reported on mortality in seven ART sites in Latin America and the Caribbean. Median baseline CD4 cell counts in these cohorts ranged from 79 to 163 cells/ml. Overall mortality at 1 year was 8.3% [95% confidence interval (CI) 7.6-9.1], but ranged from 2.6 to 13.0% [6 ] . In south-east Asia, the national ART programme in Thailand treated over 58 000 patients in 839 healthcare facilities between 2002 and 2007 and reported a 1-year mortality of 11% [8 ], which is similar to a rate of 13% in a single cohort in neighbouring Cambodia [9] . Thus, mortality rates in ART programmes are higher in resource-limited settings than in industrialized countries, but are heterogeneous with generally much higher rates in sub-Saharan Africa compared with other regions [5 ] .
Temporal distribution of mortality
In most cohorts mortality risk is substantially higher in the first few months of ART, especially in those with the greatest overall cumulative mortality [5 ,6 ,8 ] . This finding is illustrated by comparison of data from South Africa and Switzerland ( Fig. 1) [10]. Compared with the Swiss cohort, those individuals treated in South Africa had more advanced immunodeficiency at baseline and yet similar virological and immunological responses to ART. It is clearly seen that the great disparity in mortality risk was particularly marked within the first 3-6 months of treatment (Fig. 1 ).
The immunological response to ART is the key modifiable variable that is likely to explain temporal changes in mortality risk [11 ] . In a study from South Africa, changes in CD4 cell counts measured every 4 months during ART were directly related to changes in mortality risk ( Fig. 2a ). Mortality rates decreased rapidly as CD4 cell counts increased during early ART. However, once CD4 cell counts exceeded a threshold of 200 cells/ml, no further significant reductions in mortality were observed during ongoing CD4 cell count recovery [11 ] . Those patients with poor CD4 cell count recovery, however, remained at high mortality risk.
Mortality risk factors
Baseline risk factors for death are generally indicative of advanced immunodeficiency -low blood CD4 cell counts, advanced WHO clinical stage of disease, low body mass index and anaemia [4,5 ,6 ,8 ,13] . Patients enrolling in a South African ART programme with CD4 cell counts less than 100 cells/ml had approximately twice the cumulative mortality risk of patients enrolling with CD4 cell counts greater than 100 cells/ml ( Fig. 3) . A key overall conclusion of these studies is the need to provide ART to patients earlier in the disease course. Confirming the findings of previous publications [5 ], recent studies have also specifically highlighted men as having higher risk of early mortality compared with women, which is only in part explained by late presentation [8 ,14,15] .
The need to pay for treatment is another strong predictor of poor treatment outcomes and it is clear that provision of free treatment is essential [4, 16, 17] . Macro-economic factors may also be important, with lower national gross domestic product (GDP) per capita being broadly associated with poorer treatment outcomes ( Fig. 4 ). During the initial months of ART in patients with advanced immunodeficiency, medical management can be complex and resource-intensive. Thus, mortality rates may in part be higher in resource-constrained environments as a result of limitations in healthcare provision.
Causes of death
Very few data are available concerning the key causes of death during early ART and these data are largely based on clinical assessments rather than postmortem examinations. Comprehensive studies of the causes of death in different geographical regions are needed. In cohort studies from sub-Saharan Africa, the most commonly identified causes of death were tuberculosis (TB), cryptococcal meningitis, acute sepsis, Kaposi's sarcoma and wasting syndrome/ chronic diarrhoea [5 ,19 ] . In Haiti wasting syndrome was by far the commonest cause [20, 21] . In India, most deaths were reported as being due to TB, Pneumocystis jirovecii pneumonia, cerebral toxoplasmosis and cerebrovascular disease [22] .
Patients with prevalent TB at ART initiation have high mortality risk [23] [24] [25] [26] . However, a study from South Africa suggested that prevalent TB was not an independent risk factor for death but might simply reflect an association with advanced immunodeficiency in that setting [27 ] . Although this finding is consistent with data from other African cohorts [28, 29] , these analyses may fail to account for deaths occurring very early during TB treatment prior to ART initiation and also for the high burden of unascertained TB in this patient group [30] .
Consistent with previous data from Africa [23, 24] , a study from Haiti found that patients who develop TB during the first 3 months of ART have high (27%) mortality risk during the first year of ART [25] . This study also reported that the mortality risk of such patients greatly exceeded that of a comparator group consisting of pooled data from patients with either prevalent TB at baseline or incident TB presenting after 3 months of ART. Selection and survival biases, however, may in part account for this apparent difference [31] .
It has been speculated that immune reconstitution disease might be associated with increased mortality risk, although it should be borne in mind that this complication develops in those with the most advanced immunodeficiency who have high preexisting risk. Overall mortality associated with TB immune reconstitution disease, however, appears to be low [19 ,32] . Even among patients with involvement of the central nervous system, just 3 of 23 (13%) patients died during 6 months follow-up in a recent study from South Africa, although some were lost to follow-up [33] . In Uganda where Kaposi's sarcoma-associated immune reconstitution disease is relatively frequent, it is, nevertheless, rarely life-threatening [34] . Cryptococcal meningitis and cryptococcal immune reconstitution disease have been highlighted as important causes of mortality [19 ,35-38] . Cryptococcal antigenaemia present at baseline has been found to be an independent risk factor for mortality in a study from South Africa [39 ] , potentially providing a means to direct pre-emptive treatment.
Morbidity
Key causes of serious morbidity are likely to largely reflect the causes of death described above and to vary substantially between geographical regions. Detailed studies of morbidity during ART, however, are relatively few with the exception of TB.
Bacterial sepsis
In a West African study cohort with a median baseline CD4 cell count of 252 cells/ml, the two key causes of severe morbidity were identified as TB and invasive bacterial infections [40] . Bacterial diseases were predominantly episodes of pneumonia, bacteraemia, enteritis and pyelonephritis, and the most commonly isolated pathogens were Streptococcus pneumoniae, nontyphoidal
Salmonella and Escherichia coli [40] . Gastrointestinal mucosal dysfunction, which has emerged as an important component of HIV pathogenesis [41] , might serve as an important factor underlying systemic Gram-negative sepsis and wasting syndrome.
Tuberculosis TB incidence rates are very high during the initial months of ART and decrease with increasing duration of treatment [23, 24, [42] [43] [44] (Fig. 5 ). Although overall rates are much higher in resource-limited settings, the proportionate reduction in rates during ART is similar in high-income and low-income settings [44] . In a South African study, TB risk was strongly associated with changes in CD4 cell counts measured serially during ART [12 ] . The risk was almost 10-fold higher when patients had CD4 cell counts less than 100 cells/ml compared with when counts exceeded 500 cells/ml (Fig. 2b) [12 ]. In contrast to mortality ( Fig. 2a ), substantial rates of TB persisted at CD4 cell counts of 200-500 cells/ml (Fig. 2b ).
This South African study also found that during longterm ART, there was a substantial increase in the TB incidence rate (1.7-fold) during the first 4 months of ART that was not explained by CD4 cell counts and other covariates. From these data, the authors reasoned that approximately 40% of the TB cases presenting in the first 4 months of ART were likely to be attributable to immune-mediated 'unmasking' of sub-clinical TB that was not recognized at baseline [12 ,45] . This finding is supported by subsequent findings in the same cohort that systematic culture-based screening detected a very high prevalence (25%) of sputum culture-positive disease at baseline [46 ] . Much of this disease was sub-clinical or minimally symptomatic.
Immune reconstitution disease
In addition to TB, a range of other opportunistic infections is associated with development of immune reconstitution disease. In a prospective South African cohort with a median baseline CD4 cell count of 115 cells/ml, 10% (n ¼ 44) of patients developed immune reconstitution disease during the first 6 months of ART [47 ] . Almost half were associated with TB and a majority of the remainder were associated with cutaneous abscesses and folliculitis, varicella zoster, herpes simplex, cryptococcal meningitis, molluscum contagiosum and Kaposi's sarcoma. Although most cases were mild, one quarter of cases required hospital admission and two (4.5%) resulted in death (one case of TB and one case of cryptococcal disease) [47 ] . The overlap between paradoxical immune reconstitution disease in patients with multidrug-resistant TB (MDR-TB) has been highlighted in South Africa [48]; this fact complicates both diagnosis and management.
Higher rates of morbidity and mortality in lowresource settings
Much higher rates of early morbidity and mortality among patients receiving ART in resource-limited settings compared with high-income settings are only partially explained by the presentation of patients with more advanced immunodeficiency [4,5 ,6 ,8 ]. This situation may reflect much higher event frequencies during the natural history of HIV in resource-limited settings [49] . For example, in a South African natural history cohort, patients with CD4 cell counts in the range 50-200 cells/ml who have WHO stage 1 and 2, stage 3 or stage 4 diseases had very high 6-month mortality risks of 3-5, 6-12 and 14-22%, respectively [49] . This fact has important implications for the appropriate CD4 cell count thresholds at which to start ART as discussed below.
Strategies to reduce early morbidity and mortality
A number of strategies are likely to be needed to reduce early morbidity and mortality during ART.
Earlier HIV diagnosis
A critical stumbling block is that most infected people do not know their HIV status and most HIV diagnoses are only made once patients present to the health services with WHO stage 3 or stage 4 (i.e. advanced symptomatic) diseases. Such patients by definition have a high burden of morbidity and high mortality risk [49] .
Revised WHO guidelines now recommend that all individuals accessing healthcare services in high HIV prevalence settings (antenatal prevalence >1%) should be tested for HIV unless they specifically opt out [50] . In a community-based study in South Africa in which testing increased from 4 to 20% between 2001 and 2006, however, median CD4 cell counts and WHO stage of disease among newly diagnosed patients remained stable rather than improving [51] . Rates of HIV testing may need to be even more radically improved to promote earlier diagnosis and should also be provided outside the context of healthcare facilities.
Availability of CD4 cell count testing
CD4 cell count testing needs to be scaled up at the district and health centre level to assess ART eligibility. With the current impetus to decentralize HIV care and treatment services to more peripheral sites, this approach will require much simpler technology such as a point-ofcare CD4 cell count tests, which are currently under development and evaluation.
Pre-antiretroviral therapy care
The majority of health services in sub-Saharan Africa fail the HIV-infected people who are not yet eligible for ART and the concept of 'pre-ART' care needs to be championed. A package of regular care and support that includes clinical assessment, CD4 cell count measurement and trimethoprim-sulphamethoxazole (co-trimoxazole) and isoniazid preventive therapy would go a long way to decreasing subsequent late presentation and high 22 Use of antiretroviral therapy in low-and middle-income countries Months ART
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early mortality on ART. The mortality risk of patients just prior to starting ART is extremely high [37, 52] and delays within the health system need to be minimized.
Guidelines recommending earlier antiretroviral therapy
Current international [53] and national guidelines in resource-limited settings recommend starting treatment at CD4 cell counts of either up to 200 cells/ml, 250 cells/ml or 350 cells/ml. Observational data from South Africa, however, show that the 12-month mortality for untreated patients with CD4 cell counts of 200-350 cells/ml is 22% [54] compared to 4% in industrialized settings [55] . These data strongly suggest the need for earlier ART initiation as has been clearly demonstrated in the CIPRA HT001 trial from Haiti. This relatively small randomized controlled study (n ¼ 816) compared initiation of ART at CD4 cell counts between 200 and 350 cells/ml versus deferral of ART until the CD4 cell count had decreased to less than 200 cells/ml [56 ] . The mortality rate was four-fold higher and the TB rate two-fold higher in the deferred treatment arm, providing the first data from a randomized study as compelling evidence to support earlier ART initiation in resource-limited settings.
Co-trimoxazole prophylaxis WHO/UNAIDS published provisional and updated recommendations in 2000 and 2006 for prophylaxis with co-trimoxazole in all patients with symptomatic HIV infection in resource-limited settings [57] . Many countries, however, have not widely implemented this important intervention for a variety of reasons, including concerns over efficacy in the context of high rates of resistant bacteria. Thus, a further randomized controlled trial was completed in one such country (Zambia) in 2008, which confirmed that this approach is a safe intervention that reduces mortality among HIV-infected patients with TB [58] . In an ART programme in Cambodia, co-trimoxazole use was associated with an 85% reduction in adjusted hazards of death with benefit observed among those with baseline CD4 cell counts less than 200 cells/ml [18] .
Tuberculosis screening and prophylaxis
In 2008, the WHO launched the three 'I's policy -a new initiative to reduce the burden of TB in HIV-infected people [59] . This comprises the use of intensified case finding, isoniazid prophylaxis and infection control to be scaled up in tandem with ART.
The tools available for intensified case finding in patients with advanced HIV infection are blunt, however [60] .
Recent studies from South Africa found a prevalence of sputum culture-positive TB of 20-25% in patients just prior to ART initiation [46 ,61], but culture-based diagnosis was slow, the sensitivity of fluorescence smear microscopy was less than 20% and chest radiology performed poorly [62] . These data suggest the potential need for routine culture-based screening in this setting and the need for new rapid and point-of-care diagnostics.
Following the fatal outbreak of MDR-TB and extensively drug-resistant TB (XDR-TB) among ART patients attending a facility in KwaZulu Natal, South Africa, in 2005-2006 [63] , the WHO has recommended the implementation of molecular line-probe assays in resourcelimited settings [64] . This should greatly expedite the diagnosis of MDR-TB.
Isoniazid prophylaxis substantially reduces TB risk and shows a trend towards a reduction in mortality in patients not receiving ART and who have a positive tuberculin skin test [65] . Using observational data from Brazil and South Africa, it has been suggested that there may also be an additive effect of isoniazid preventive therapy when administered prior to or during ART [66, 67] . A number of considerations, however, suggest that starting isoniazid preventive therapy at the same time as ART initiation might be inadvisable in patients with low CD4 cell counts since there may be a high prevalence of active undiagnosed TB [46 ,61] , the negative predictive value of TB screening algorithms is limited [60] and combined use of isoniazid during the initial weeks of stavudine-containing ART is associated with a high incidence of peripheral neuropathy [68] . Initiation of isoniazid after completion of the initial months of ART has therefore been suggested as an alternative strategy [12 ] .
Screening and prophylaxis for cryptococcal disease
Two retrospective studies from Africa have found that detectable cryptococcal antigenaemia in patients starting ART is an independent predictor of mortality [37, 69] . In the more recent study, the prevalence of antigenaemia was 13% among patients with CD4 cell counts less than 100 cells/ml and an antigen titre of at least 1:8 was 100% sensitive and 96% specific for predicting development of cryptococcal meningitis during the first year of ART [39 ] . Use of this as a screening test pre-ART might permit implementation of a targeted pre-emptive treatment strategy.
Importantly, a study from Cambodia found that use of fluconazole prophylaxis during ART was associated with a 50% reduction in adjusted hazards of death, with benefit being observed among those with baseline CD4 cell counts less than 100 cells/ml [18] . No comment was made on whether this was due to prevention of cryptococcosis, oesophageal candidiasis or other locally prevalent fungal pathogens such as Penicillium marneffei.
Optimized management of opportunistic diseases
Management strategies need to be optimized to address serious and life-threatening morbidity. Expertise in the treatment of TB and HIV concurrently is gradually evolving through observational studies [70 ] . Use of efavirenz rather than nevirapine-containing ART appears to be preferable when combined with rifampicin-containing TB treatment, with regard to both ART efficacy and toxicity [71] . Results of randomized controlled trials informing the optimum time to initiate ART during TB treatment are awaited, but interim results from the South African SAPIT trial found a very high mortality among patients deferring ART initiation to the end of TB of the 6-month treatment phase compared with initiation during or at the end of the 2-month intensive phase [72] . MDR-TB and HIV co-infection carries a poor prognosis and much remains to be learned about MDR-TB management during ART.
A randomized placebo-controlled trial of corticosteroids has been evaluated in the management of moderate (nonlife-threatening) TB immune reconstitution disease in South Africa [73 ] . Although no mortality benefit was observed, there was a significant reduction in the need for hospitalization and interventions in the treatment arm.
Optimum regimens are needed for treatment of cryptococcal meningitis. Although high-dose intravenous amphotericin and flucytosine evaluated in South Africa may be the ideal [74] , this is neither logistically feasible nor affordable in many low-income settings. Data from Uganda suggest oral fluconazole at a high dose (1200 mg per day) may be more rapidly fungicidal than currently used lower doses [75 ] .
Improving treatment access and retention in care
Recognition of and pragmatic solutions to address the factors that hinder treatment access and retention in care are essential. These include the need for free treatment [4, 16, 17] , the critical issue of high transport costs to and from clinics [76] , the importance of uninterrupted drug supplies in health facility pharmacies and decentralization of services so that they are nearer to patients' homes. Every attempt must be made by ART clinics to link their services with the community and particularly with associations of people living with HIV/AIDS. Care packages such as home treatment of opportunistic infections, support to family carers, referral of patients with possible adverse drug reactions, continuing adherence counselling and defaulter tracing are, not surprisingly, associated with better ART treatment outcomes [77] . The community is an unrecognized and largely unexploited resource that could play an important contributory role in improving ART retention provided there are well-defined structured links to the health services.
Conclusion
Rates of early morbidity and mortality are much higher among patients treated in resource-limited settings com-pared with those in high-income settings. These are, however, very heterogeneous across resource-limited settings and a range of biomedical, economic and social factors may underlie this. The high burden of disease needs to be addressed by strategies that broadly enhance earlier HIV diagnosis and access to ART, screening and prophylaxis for opportunistic infections, optimized opportunistic disease management and strengthening of ART services. Managing patients with advanced immunodeficiency and high rates of morbidity and mortality is a major challenge using the simplified public health approach to ART delivery. Nevertheless, this has been very successful indeed in enabling rapid expansion to treatment to permit millions of people to gain the benefits of ART.
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